Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Belén Otero-Carrasco has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EVALUATION OF A GENERATIVE AI TOOL IN DATA PROGRAMMING EDUCATION

    by Belén Otero-Carrasco, Belén Ríos-Sánchez, Alejandro Rodríguez González, Guillermo Vigueras

  • Rare Diseases and Orphan Drugs: Innovation Through Repurposing Strategies

    by Belén Otero-Carrasco, Alejandro Rodríguez-González

  • Open Access

    Accelerating Drug Repurposing with AI: The Role of Large Language Models in Hypothesis Validation

    by Iratxe Zunzunegui Sanz, Belén Otero-Carrasco, Alejandro Rodríguez-González

    Drug repurposing accelerates drug discovery by identifying new therapeutic uses for existing drugs, but validating computational predictions remains a challenge. Large Language Models (LLMs) offer a potential solution by analyzing biomedical literature to assess drug-disease associations. This study evaluates four LLMs (GPT-4o, Claude-3, Gemini-2, and DeepSeek) using ten prompt strategies to validate repurposing hypotheses. The best-performing prompts and models were tested on 30 pathway-based cases and 10 benchmark cases. Results show that structured prompts enhance LLM accuracy, with GPT-4o and DeepSeek emerging as the most reliable models. Benchmark cases achieved significantly higher accuracy, precision, and F1-score (p < 0.001), while recall remained consistent across datasets. These findings highlight LLMs’ potential in drug repurposing validation while emphasizing the need for structured prompts and human oversight.


  • Prioritization of Potential Drugs Through Pathway-Based Drug Repurposing and Network Proximity Analysis

    by Belén Otero-Carrasco, Lucía Prieto-Santamaría, Alejandro Rodríguez-González

    Drug repurposing is an effective strategy to identify novel therapeutic options by leveraging existing drugs with known mechanisms of action and safety profiles. This work introduces a pathway-based drug repurposing approach that combines protein-protein interaction (PPI) networks and transcriptomic data to prioritize candidate drugs. The underlying assumption is that if disease 1 and disease 2 are both associated with the same biological pathway, then drugs known to be effective for disease 2 may be potential treatments for disease 1. To explore these relationships, disease–pathway–drug triplets are constructed. Genes shared between disease 1 and the associated pathway are identified, and their proximity is calculated within the PPI network using a Z-score based on random permutations. Candidate drugs for disease 2 are then analyzed using the Connectivity Map data, assessing whether their up- or down-regulated gene signatures are enriched for the genes contributing to the proximity between disease 1 and the pathway. This integration enables the ranking of candidate drugs based on their potential biological impact on disease 1. Finally, top-ranked drug–disease associations are evaluated through manual curation of the scientific literature to assess existing evidence supporting the proposed repurposing hypothesis.


  • Exploring Protein Patterns, Cavity Interactions, and Therapeutic Insights in Cancer

    by Paloma Tejera-Nevado, Belén Otero-Carrasco, Alejandro Rodríguez-González

    Protein sequence alignments are essential for identifying proteins' shared structural and functional features. Detecting short amino acid sequences, termed patterns, across lung cancer and other related datasets facilitates the identification of relevant features. This study builds on previous findings by exploring proteins that share common patterns already identified. Using sequence matching at 5 % and 10 % occurrence thresholds, we identified 2,368 and 47 patterns, respectively. To reduce complexity and refine the dataset, shorter patterns from the 10 % occurrence streamlined the analysis by isolating highly relevant patterns while reducing redundancy among proteins sharing sequence segments. Subsequent analyses integrated structural predictions for protein folding comparison, enabling the detection of patterns in different proteins and the identification of potential key residues. During cavity detection prediction, some amino acids were inspected in detail to assess their impact on protein function and their relevance in drug-target interactions. These insights were considered during docking studies, focusing on proteins used in treatments with pre-described ligands. By connecting raw sequence data to folding structures and functional features, we identified critical protein cavities that underscore the role of mutations in altering protein behavior and influencing drug-target interactions. These findings highlight protein activity's structural foundations and their importance in understanding cancer biology. By uncovering conserved sequence patterns and their structural implications, this study provides insights into potential biomarkers and therapeutic targets, that could aid in developing more effective cancer treatments.

  • Accelerating Drug Repurposing with AI: The Role of Large Language Models in Hypothesis Validation

    by Iratxe Zunzunegui Sanz, Belen Otero-Carrasco, Alejandro Rodriguez-Gonzalez

    Drug repurposing accelerates drug discovery by identifying new therapeutic uses for existing drugs, but validating computational predictions remains a challenge. Large Language Models (LLMs) offer a potential solution by analyzing biomedical literature to assess drug-disease associations. This study evaluates four LLMs (GPT-40, Claude-3, Gemini-2, and DeepSeek) using ten prompt strategies to validate repurposing hypotheses. The best-performing prompts and models were tested on 30 pathway- based cases and 10 benchmark cases. Results show that structured prompts enhance LLM accuracy, with GPT-40 and DeepSeek emerging as the most reliable models. Benchmark cases achieved significantly higher accuracy, precision, and F1-score (p < 0.001), while recall remained consistent across datasets. These findings highlight LLMs' potential in drug repurposing validation while emphasizing the need for structured prompts and human oversight.


  • Open Access

    Prioritization of Potential Drugs Through Pathway-Based Drug Repurposing and Network Proximity Analysis

    by Belén Otero-Carrasco, Lucía Prieto-Santamaría, Alejandro Rodríguez-González

    Drug repurposing is an effective strategy to identify novel therapeutic options by leveraging existing drugs with known mechanisms of action and safety profiles. This work introduces a pathway-based drug repurposing approach that combines protein-protein interaction (PPI) networks and transcriptomic data to prioritize candidate drugs. The underlying assumption is that if disease 1 and disease 2 are both associated with the same biological pathway, then drugs known to be effective for disease 2 may be potential treatments for disease 1. To explore these relationships, disease–pathway–drug triplets are constructed. Genes shared between disease 1 and the associated pathway are identified, and their proximity is calculated within the PPI network using a Z-score based on random permutations. Candidate drugs for disease 2 are then analyzed using the Connectivity Map data, assessing whether their up- or down-regulated gene signatures are enriched for the genes contributing to the proximity between disease 1 and the pathway. This integration enables the ranking of candidate drugs based on their potential biological impact on disease 1. Finally, top-ranked drug–disease associations are evaluated through manual curation of the scientific literature to assess existing evidence supporting the proposed repurposing hypothesis.

  • Open Access

    Exploring Protein Patterns, Cavity Interactions, and Therapeutic Insights in Cancer

    by Paloma Tejera-Nevado, Belén Otero-Carrasco, Alejandro Rodríguez-González

    Protein sequence alignments are essential for identifying proteins’ shared structural and functional features. Detecting short amino acid sequences, termed patterns, across lung cancer and other related datasets facilitates the identification of relevant features. This study builds on previous findings by exploring proteins that share common patterns already identified. Using sequence matching at 5% and 10% occurrence thresholds, we identified 2,368 and 47 patterns, respectively. To reduce complexity and refine the dataset, shorter patterns from the 10% occurrence streamlined the analysis by isolating highly relevant patterns while reducing redundancy among proteins sharing sequence segments. Subsequent analyses integrated structural predictions for protein folding comparison, enabling the detection of patterns in different proteins and the identification of potential key residues. During cavity detection prediction, some amino acids were inspected in detail to assess their impact on protein function and their relevance in drug-target interactions. These insights were considered during docking studies, focusing on proteins used in treatments with pre-described ligands. By connecting raw sequence data to folding structures and functional features, we identified critical protein cavities that underscore the role of mutations in altering protein behavior and influencing drug-target interactions. These findings highlight protein activity’s structural foundations and their importance in understanding cancer biology. By uncovering conserved sequence patterns and their structural implications, this study provides insights into potential biomarkers and therapeutic targets, that could aid in developing more effective cancer treatments.


  • Open Access

    Finding patterns in lung cancer protein sequences for drug repurposing

    by Belén Otero-Carrasco, Paloma Tejera Nevado, Rafael Artiñano Muñoz, Gema Díaz Ferreiro, Aurora Pérez Pérez, Juan Pedro Caraça-Valente Hernández, Alejandro Rodríguez-González

    Proteins are fundamental biomolecules composed of one or more chains of amino acids. They are essential for all living organisms, contributing to various biological functions and regulatory processes. Alterations in protein structures and functions are closely linked to diseases, emphasizing the need for in-depth study. A thorough understanding of these associations is crucial for developing targeted and more effective therapeutic strategies.Computational analyses of biomedical data facilitate the identification of specific patterns in proteins associated with diseases, providing novel insights into their biological roles. This study introduces a computational approach designed to detect relevant sequence patterns within proteins. These patterns, characterized by specific amino acid arrangements, can be critical for protein functionality. The proposed methodology was applied to proteins targeted by drugs used in lung cancer treatment, a disease that remains the leading cause of cancer-related mortality worldwide. Given that non-small cell lung cancer represents 85–90% of all lung cancer cases, it was selected as the primary focus of this study.Significant sequence patterns were identified, establishing connections between drug-target proteins and proteins associated with lung cancer. Based on these findings, a novel computational framework was developed to extend this pattern-based analysis to proteins linked to other diseases. By employing this approach, relationships between lung cancer drug-target proteins and proteins associated with four additional cancer types were uncovered. These associations, characterized by shared amino acid sequence features, suggest potential opportunities for drug repurposing. Furthermore, validation through an extensive literature review confirmed biological links between lung cancer drug-target proteins and proteins related to other malignancies, reinforcing the potential of this methodology for identifying new therapeutic applications.


  • Open Access

    Review of: "Strategies for Robust, Accurate, and Generalisable Benchmarking of Drug Discovery Platforms"

    by Belén Otero Carrasco

    The article addresses a critical need in drug discovery by improving benchmarking protocols, which is essential for reducing costs and inefficiencies in pharmaceutical development. It introduces novel metrics, such as "nAIA" and "nNDCG," which enhanc...